GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (LTS:0AB6) » Definitions » Liabilities-to-Assets

Hyloris Pharmaceuticals (LTS:0AB6) Liabilities-to-Assets : 0.19 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Hyloris Pharmaceuticals Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Hyloris Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 was €8.79 Mil. Hyloris Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was €47.61 Mil. Therefore, Hyloris Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.19.


Hyloris Pharmaceuticals Liabilities-to-Assets Historical Data

The historical data trend for Hyloris Pharmaceuticals's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals Liabilities-to-Assets Chart

Hyloris Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
Get a 7-Day Free Trial 2.70 0.15 0.24 0.11 0.19

Hyloris Pharmaceuticals Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.17 0.11 0.15 0.19

Competitive Comparison of Hyloris Pharmaceuticals's Liabilities-to-Assets

For the Biotechnology subindustry, Hyloris Pharmaceuticals's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyloris Pharmaceuticals's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's Liabilities-to-Assets falls into.



Hyloris Pharmaceuticals Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Hyloris Pharmaceuticals's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=8.79/47.612
=0.18

Hyloris Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as

Liabilities-to-Assets (Q: Dec. 2023 )=Total Liabilities/Total Assets
=8.79/47.612
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hyloris Pharmaceuticals  (LTS:0AB6) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Hyloris Pharmaceuticals Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyloris Pharmaceuticals (LTS:0AB6) Business Description

Traded in Other Exchanges
Address
Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.

Hyloris Pharmaceuticals (LTS:0AB6) Headlines

No Headlines